Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.

Introduction: The treatment response and outcome in acute myeloid leukaemia (AML) is heterogeneous.

Aim: To analyze the prognostic parameters of AML at presentation.

Methods: The total sample of 44 AML patients was analyzed on the basis of age <55 and ≥55 years, sex, WBC count <50x10//l and ≥50x10//l, the Hb concentration <100 g/l and ≥100 g/l, PLT count <100x10//l and ≥100x10//l, Karnofsky score <60% and >60%, cytogenetics, CD56 expression, morphological type and types of treatment (standard and reduced induction chemotherapy, high-dose chemotherapy/stem cell transplantation - autologous and HLA matched, related, allogeneic, together and separately).

Myeloprolipherative disorder type chronic myeloid leukemia--eosinophilic form.

Chronic eosinophilic leukemia (CEL) is a very rare form of leucemia in the western world. Adequate response is seldomly achieved after treatment with corticosteroids, interferon-alfa (INF-alfa) and medications containing hydroxi-urea (Litalir). The study presents a patient with CEL with no initial therapeutic response to the use of corticosteroids, INF-alfa and hydroxy-urea, and with neither clinical nor hematological response.

The role of predictor factors in patients with non Hodgkin lymphoma in relation to the applied therapy.

Unlabelled: Lymphoma are defined as malignant neoplasms of immune system, or in other words the neoplasms of lymphocytes and their precursory cells which form the basic cellular elements of the immune system. The heterogeneity of lymphoma from the aspect of morphology and the aspect of clinical manifestations demanded the identification of all possible parameters which could influence the course and outcome of the disease on every single level. The aim of our study was to investigate which of the prognostic factors confirms the statistical importance of the remission state and overall survival and if the patients treated with standard PHT (poly chemotherapy) protocols with the addition of anti-CD20 antibody show more clinical benefit.

Morphometric angiogenesis parameters for indolent and aggressive non-Hodgkin's lymphoma.

There is much evidence about importance of angiogenesis in development and progression of solid tumors. The role of angiogenesis, as an indicator of higher malignant potential in non-Hodgkin's lymphoma, is not clear at the moment. Morphometric characteristics of microvessels in lymph node sections, in previously untreated patients with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and diffuse large B-cell lymphoma (DLBCL), were studied and relationship between angiogenesis and histological malignancy grade of NHL was also evaluated.

[Case report of successful treating of refractory form of chronic lymphatic leukemia in Binnet C stage by using anti-CD52 antibodies].

Chronic lymphatic leukemia (CLL) is the most frequent type of leukemia in western world, and a choice of treatment modality depends on current stage of disease. Clinical condition of patient considered as Binnet C stage, requires treatment. Standard polyhemiotherapy (FC protocol) does not always warrant adequate and satisfactory response.